Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hemodynamic Effects of Compression in POTS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03484273
Recruitment Status : Recruiting
First Posted : March 30, 2018
Last Update Posted : July 27, 2018
Sponsor:
Information provided by (Responsible Party):
Dr. Satish Raj, University of Calgary

Brief Summary:

When an individual with Postural Tachycardia Syndrome (POTS) stands up, their heart rate increases significantly (>30BPM) and they may experience symptoms such as lightheadedness, dizziness, shortness of breath, nausea and mental confusion.

One commonly prescribed treatment for POTS is compression garments. Compression garments squeeze veins to help return blood back to the heart, which may decrease heart rate and symptoms on standing. However, there is little research about the effectiveness of compression in adults with POTS.

In this study, the investigators will use the Lifewrap garment, which compresses the abdomen, pelvis and lower extremities, to evaluate the effectiveness of compression in POTS. The investigators will use a head up tilt (HUT) which will simulate standing. The study participant will participate in 4x 10 minute HUTs wearing 4 different compression configurations:

  1. full abdomen and lower extremity compression
  2. abdominal only compression
  3. leg only compression
  4. No compression

The investigators hypothesize that with full compression, the participant's heart rate increase from lying down to upright will be lower than when they are not wearing any compression. The investigators will also ask the participant about their symptoms when they are upright.

The results of this study could demonstrate the potential benefits of compression and what configuration is most effective. These findings could rapidly translate to the clinical setting, providing improved care.


Condition or disease Intervention/treatment Phase
Postural Tachycardia Syndrome Device: LifeWrap Compression Garment Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: There will be 4 compression conditions based on strap configuration of the Lifewrap garment: full abdominal and lower extremity compression, abdominal only compression, lower extremity only compression and no compression. The order of these interventions will be randomized.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Body Compression in Postural Tachycardia Syndrome (POTS): Effects on Orthostatic Tolerance
Actual Study Start Date : July 12, 2018
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : June 2020

Arm Intervention/treatment
Experimental: Full Compression
The LifeWrap compression garment will be fully secured with all straps.
Device: LifeWrap Compression Garment
Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.

Experimental: Abdominal and Pelvic Compression
The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
Device: LifeWrap Compression Garment
Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.

Experimental: Lower Limb Compression
The Lifewrap compression garment calf and ankle straps only will be secured.
Device: LifeWrap Compression Garment
Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.

No Intervention: No Compression
None of the LifeWrap compression garment straps will be secured.



Primary Outcome Measures :
  1. Orthostatic Heart Rate (HR) Change [ Time Frame: Maximum HR between 5-10min HUT MINUS the baseline (pre-tilt) HR ]
    The primary outcome measure will be the magnitude of HR change from supine to HUT (max HR between 5-10 min of HUT) for each study arm.


Secondary Outcome Measures :
  1. Maximum Upright Heart Rate [ Time Frame: During minutes 5-10 of the HUT ]
    The maximum heart rate during minutes 5-10 of each HUT. The maximum heart rate during each of the study arms will be compared.

  2. Differences in Vanderbilt Orthostatic Symptom Score (VOSS) Symptom Rating [ Time Frame: After t=10 of the 10min HUT (or sooner if HUT has to be terminated early due to symptoms) ]

    Subjective symptom scoring as reported by participant during each study arm. The VOSS evaluates 9 symptoms on a 0 to 10 scale with 0 being no symptom to 10 being worst ever symptom. The total score ranges from 0-90, with a higher score being more severe symptoms.

    The 9 symptoms are mental clouding, blurred vision, shortness of breath, rapid heartbeat, tremulousness, chest discomfort, headache, lightheadedness, and nausea. The participant's VOSS score will be compared across the 4 arms of this study.

    The VOSS score has been previously used in multiple publications


  3. Change in blood pressure (BP) [ Time Frame: During the baseline before the HUT and the BP correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals. ]
    Change in continuous blood pressure between supine and HUT during each study arm.

  4. Changes in Stroke Volume [ Time Frame: During the baseline before the HUT and the SV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals. ]
    Change in Stroke Volume from supine to HUT in each of the study arms.

  5. Change in Cardiac Output (CO) [ Time Frame: During the baseline before the HUT and the CO correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals. ]
    Change in Cardiac Output from supine to HUT in each of the study arms.

  6. Change in Systemic Vascular Resistance (SVR) [ Time Frame: During the baseline before the HUT and the SVRcorrelating with the maximum HR during 5-10 min HUT, recorded at 1min intervals. ]
    Change in Systemic Vascular Resistance from supine to HUT in each of the study arms.

  7. Change in Cerebral Blood Flow Velocity (CBFV) [ Time Frame: During the baseline before the HUT and the CBFV correlating with the maximum HR during 5-10 min HUT, recorded at 1 min intervals. ]
    Change in cerebral blood flow from supine to HUT in each of the study arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Physician diagnosis of Postural Tachycardia Syndrome (POTS)
  • Age 18-60 years (we are an adult group and we do not see pediatric patients clinically and do not have appropriate pediatric expertise)
  • Male and Female
  • Able and willing to provide informed consent
  • Ability to travel to Libin Cardiovascular Institute of Alberta Autonomic Testing Lab at the University of Calgary, Calgary, AB.

Exclusion Criteria:

  • Overt cause for postural tachycardia, i.e., acute dehydration
  • Participants with somatization or severe anxiety symptoms will be excluded (as they may not tolerated study procedures)
  • Pregnant women
  • Inability to tolerate compression garment for the duration of the study
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03484273


Contacts
Layout table for location contacts
Contact: Satish R Raj, MD, MSCI 403 210-7627 autonomic.research@ucalgary.ca

Locations
Layout table for location information
Canada, Alberta
Unversity of Calgary Recruiting
Calgary, Alberta, Canada
Contact: Kate Bourne, B.Sc.    403 210-7627    kate.bourne1@ucalgary.ca   
Contact: Satish R Raj, MD       autonomic.research@ucalgary.ca   
Principal Investigator: Satish R. Raj, MD         
Principal Investigator: Robert Sheldon, MD         
Sponsors and Collaborators
University of Calgary
Investigators
Layout table for investigator information
Principal Investigator: Satish R Raj, MD, MSCI University of Calgary
  Study Documents (Full-Text)

Documents provided by Dr. Satish Raj, University of Calgary:

Layout table for additonal information
Responsible Party: Dr. Satish Raj, Professor; Medical Director, Calgary Autonomic Investigation & Management Clinic, University of Calgary
ClinicalTrials.gov Identifier: NCT03484273     History of Changes
Other Study ID Numbers: REB17-2393
First Posted: March 30, 2018    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr. Satish Raj, University of Calgary:
Tilt Table
Compression
Dysautonomia
POTS

Additional relevant MeSH terms:
Layout table for MeSH terms
Postural Orthostatic Tachycardia Syndrome
Syndrome
Tachycardia
Disease
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases